Tuhura Biosciences, Inc/nv

TuHura Biosciences, Inc. has drawn an additional $1.5 million under its existing revolving credit facility for general corporate purposes.

TuHura Biosciences, Inc. has drawn an additional $1.9 million under its revolving credit facility for general corporate purposes.

TuHURA Biosciences has initiated its first drawdown of $1.7 million from a previously established $50 million revolving credit facility.

TuHURA Biosciences reports Q1 2026 financial results and secures a $50 million credit facility to extend its cash runway into 2028.

TuHURA Biosciences filed an amendment to its 8-K to correct errors in previously reported pro forma financial statements following its acquisition of Kineta.

TuHURA Biosciences has entered into a $50 million revolving credit facility with Parkview Holdings One LLC to fund operations and development programs.

TuHURA Biosciences reports Q1 2026 financial results, highlighting a $7.5 million net loss and a new $50 million credit facility to support clinical development.

TuHURA Biosciences, Inc. reported significantly increased net losses and a critical cash position for Q3 2025, raising substantial doubt about its ability to continue as a going concern, despite advancing its clinical pipeline and pursuing new financing.

TuHURA Biosciences reported a widened net loss in Q2 2025, driven by increased R&D and administrative expenses, while advancing its clinical pipeline and completing the Kineta merger.

TuHURA Biosciences announced its financial results for the first quarter of 2025, highlighting ongoing preparations for a Phase 3 trial of IFx-2.0 and the pending merger with Kineta, Inc.

TuHURA Biosciences, formerly Kintara Therapeutics, released its first quarterly report post-merger, detailing financial results and operational updates including the re-initiation of the REM-001 clinical trial.

Kintara Therapeutics announced its Q3 2024 financial results, highlighted by a merger agreement with TuHURA Biosciences and the restart of the REM-001 clinical trial, while also reporting a net loss and ongoing concerns about its ability to continue as a going concern.

TuHURA Biosciences files an amendment to its 2025 Annual Report to include missing proxy information and correct management discussion disclosures.

TuHURA Biosciences reported increased losses and substantial doubt about its ability to continue as a going concern despite advancing its immuno-oncology pipeline and securing recent financing.

TuHURA Biosciences details its 2024 financial results and provides an update on its clinical programs, including the planned Phase 3 trial for IFx-2.0 and the proposed merger with Kineta, Inc.

Kintara Therapeutics shifts its focus to REM-001 after VAL-083 fails to outperform standard care in glioblastoma, and stockholders approve a merger with TuHURA Biosciences.

TuHURA Biosciences CEO James A. Bianco reported gifting 150,000 shares of common stock to his adult sons.

TuHURA Biosciences' Chief Financial Officer, Dan Dearborn, was granted 273,696 stock options with an exercise price of $0.73, vesting over three years.

TuHURA Biosciences, Inc. CEO James A. Bianco received a supplemental grant of 610,332 stock options with an exercise price of $0.73.

TuHURA Biosciences' Chief Financial Officer, Dan Dearborn, was granted 1,531,367 stock options with an exercise price of $1.02, vesting over three years.

TuHURA Biosciences CEO James A. Bianco was granted 3,414,891 stock options with an exercise price of $1.02, vesting over three years.

TuHURA Biosciences and Kineta, Inc. stockholders have overwhelmingly approved all merger-related proposals, including an increase in TuHURA's authorized shares and reincorporation to Delaware, clearing a significant hurdle for the companies' anticipated merger.

TuHURA Biosciences announces its 2026 Annual Meeting of Stockholders to be held virtually on August 18, 2026, with key proposals including director elections, stock issuance approval, and executive compensation votes.

Kintara Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, to vote on director elections, executive compensation, and auditor ratification.

TuHURA Biosciences, a clinical-stage immuno-oncology company, filed an S-1/A registration statement for the resale of up to 9.3 million shares, following recent mergers and financing activities.

TuHURA Biosciences progresses its immuno-oncology pipeline with a Phase 3 trial initiation and strategic acquisition, while facing significant financial challenges and a need for substantial additional funding.

The Vanguard Group has filed an amended Schedule 13G, revealing a 4.44% beneficial ownership stake in TuHURA Biosciences Inc. as of September 30, 2025.

KP Biotech Group LLC has disclosed a 0.9% beneficial ownership stake in TuHURA Biosciences, Inc., holding 447,232 shares of common stock.

CA Patel F&F Investments, LLC has reported a passive beneficial ownership of 0.9% in TuHURA Biosciences, Inc., holding 447,232 shares of common stock.

The Vanguard Group has reported a 5.11% beneficial ownership stake in TuHURA Biosciences Inc., holding 2,234,240 shares of common stock.